​

CalciMedica Stock (NASDAQ:CALC)

OwnershipFinancialsChart
CalciMedica by TradingView

Previous Close

$0.66

52W Range

$0.46 - $7.20

50D Avg

$2.98

200D Avg

$2.97

Market Cap

$10.48M

Avg Vol (3M)

$1.23M

Beta

1.24

Div Yield

-

CALC Company Profile

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jun 14, 2023

Website

CALC Performance

CALC Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-23.12M$-24.20M$-38.08M
Net Income$-29.56M$-13.70M$-34.36M
EBITDA$-23.12M$-24.15M$-38.02M
Basic EPS$-1.97$-1.22$-7.65
Diluted EPS$-1.97$-1.22$-7.65

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
TVRDTvardi Therapeutics, Inc.
ELUTElutia Inc.
LVTXLAVA Therapeutics N.V.
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
RVPHReviva Pharmaceuticals Holdings, Inc.
RNXTRenovoRx, Inc.
LTRNLantern Pharma Inc.